It is thought that the secondary pathway by which AOD9604 causes fat loss, the pathway that is independent of beta-3-adrenergic receptor activation, may play a role in improving metabolic metrics even while it boosts fat loss- AOD9604 exhibits minimal side effects, high oral and excellent subcutaneous bioavailability in mice
The FDA first approved it as an appetite suppressant in 1959
BPC-157 is for patients who want to support their body's repair processes with a clinician-guided peptide protocol
This targeted mechanism allows enhanced fat oxidation and reduced lipogenesis, particularly in visceral and abdominal fat depots, making it a key subject in obesity and metabolic optimization research
Maintenance Once stores are replete, maintenance is 1mg every two to three months for deficiency of dietary origin, or every two months where there has been neurological involvement
Angiogenesis Research: Analyzing the formation of new blood vessels, a critical step in tissue repair that is heavily studied in conjunction with this peptide
